790 related articles for article (PubMed ID: 30572620)
1. Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing.
Chrysostomou AC; Stylianou DC; Constantinidou A; Kostrikis LG
Viruses; 2018 Dec; 10(12):. PubMed ID: 30572620
[TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
Poljak M; Seme K; Maver PJ; Kocjan BJ; Cuschieri KS; Rogovskaya SI; Arbyn M; Syrjänen S
Vaccine; 2013 Dec; 31 Suppl 7():H59-70. PubMed ID: 24332298
[TBL] [Abstract][Full Text] [Related]
4. Primary Care Physicians' Adherence to Expert Recommendations for Cervical Cancer Screening and Prevention in the Context of Human Papillomavirus Vaccination.
Malo TL; Perkins RB; Lee JH; Vadaparampil ST
Sex Transm Dis; 2016 Jul; 43(7):438-44. PubMed ID: 27322046
[TBL] [Abstract][Full Text] [Related]
5. An overview on the implementation of HPV vaccination in Europe.
Bonanni P; Levi M; Latham NB; Bechini A; Tiscione E; Lai P; Panatto D; Gasparini R; Boccalini S
Hum Vaccin; 2011; 7 Suppl():128-35. PubMed ID: 21245659
[TBL] [Abstract][Full Text] [Related]
6. HPV testing and vaccination in Europe.
Leeson SC; Alibegashvili T; Arbyn M; Bergeron C; Carriero C; Mergui JL; Nieminen P; Prendiville W; Redman CW; Rieck GC; Quaas J; Petry KU
J Low Genit Tract Dis; 2014 Jan; 18(1):61-9. PubMed ID: 23774078
[TBL] [Abstract][Full Text] [Related]
7. Providers' practice, recommendations and beliefs about HPV vaccination and their adherence to guidelines about the use of HPV testing, 2007 to 2010.
Berkowitz Z; Nair N; Saraiya M
Prev Med; 2016 Jun; 87():128-131. PubMed ID: 26921654
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
9. Knowledge, attitudes, and practices toward cervical cancer prevention among women in Kampong Speu Province, Cambodia.
Touch S; Oh JK
BMC Cancer; 2018 Mar; 18(1):294. PubMed ID: 29544466
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China.
Mo X; Gai Tobe R; Wang L; Liu X; Wu B; Luo H; Nagata C; Mori R; Nakayama T
BMC Infect Dis; 2017 Jul; 17(1):502. PubMed ID: 28720082
[TBL] [Abstract][Full Text] [Related]
11. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Kim JJ; Burger EA; Sy S; Campos NG
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
[TBL] [Abstract][Full Text] [Related]
12. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.
Tota J; Mahmud SM; Ferenczy A; Coutlée F; Franco EL
Sex Health; 2010 Sep; 7(3):376-82. PubMed ID: 20719230
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of HPV infection and current status of cervical cancer prevention in Greece: final results of the LYSISTRATA cross-sectional study.
Agorastos T; Chatzistamatiou K; Zafrakas M; Siamanta V; Katsamagkas T; Constantinidis TC; Lampropoulos AF;
Eur J Cancer Prev; 2014 Sep; 23(5):425-31. PubMed ID: 24977385
[TBL] [Abstract][Full Text] [Related]
14. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change.
Franco EL; Mahmud SM; Tota J; Ferenczy A; Coutlée F
Arch Med Res; 2009 Aug; 40(6):478-85. PubMed ID: 19853188
[TBL] [Abstract][Full Text] [Related]
15. Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination.
Franco EL; Ferenczy A
Future Oncol; 2007 Jun; 3(3):319-27. PubMed ID: 17547527
[TBL] [Abstract][Full Text] [Related]
16. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
Hall MT; Smith MA; Lew JB; O'Hallahan J; Fentiman G; Neal H; Sage M; Canfell K
Gynecol Oncol; 2019 Mar; 152(3):472-479. PubMed ID: 30876491
[TBL] [Abstract][Full Text] [Related]
17. Urine-based HPV testing as a method to screen for cervical cancer.
Fontenot HB
Nurs Womens Health; 2015; 19(1):59-65. PubMed ID: 25690816
[TBL] [Abstract][Full Text] [Related]
18. Effect of human papillomavirus vaccination on cervical cancer screening in Alberta.
Kim J; Bell C; Sun M; Kliewer G; Xu L; McInerney M; Svenson LW; Yang H
CMAJ; 2016 Sep; 188(12):E281-E288. PubMed ID: 27378467
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus: science and technologies for the elimination of cervical cancer.
Bosch FX
Expert Opin Pharmacother; 2011 Oct; 12(14):2189-204. PubMed ID: 21756205
[TBL] [Abstract][Full Text] [Related]
20. Impact of pap test compliance and cervical cancer screening intervals on human papillomavirus vaccine acceptance.
Ferris DG; Waller J; Dickinson A; McCracken C; Goebel A
J Low Genit Tract Dis; 2012 Jan; 16(1):39-44. PubMed ID: 22126831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]